Breaking News
January 24, 2019 - FDA authorizes marketing of new test to aid in the diagnosis of M. gen. infections
January 24, 2019 - Health Tip: Simple CPR – Drugs.com MedNews
January 24, 2019 - Diabetes in America, 3rd Edition
January 24, 2019 - Bangladesh ‘Tree Man’ returns to hospital as condition worsens
January 24, 2019 - Costs of gun-related hospitalizations, readmissions examined in study
January 24, 2019 - Good health literacy linked to better adherence to blood pressure medications among Hispanics
January 24, 2019 - Only a minority of patients in the U.S. with type 1 diabetes achieve treatment goals
January 24, 2019 - High fat reduces efficiency of the immune system to fight infectious disease
January 24, 2019 - FDA grants clearance to Hologic’s assay for detection of common sexually transmitted infections
January 24, 2019 - Study highlights need for reliable therapeutic targets for prevention, treatment of cardiovascular diseases
January 24, 2019 - Next step toward replacement therapy in type 1 diabetes
January 24, 2019 - “Scientific serendipity” identifies link between type of RNA and autism
January 24, 2019 - Trump Zeroes In On Surprise Medical Bills In White House Chat With Patients, Experts
January 24, 2019 - Unique form of chronic sinusitis found in older patients
January 24, 2019 - NUS researchers make muscle recovery easier for patients with ingenious medical device
January 24, 2019 - Specific cognitive deficits found in individuals with spinal cord injury
January 24, 2019 - An essential reference for diagnostic ultrasonography and biopsy of the thyroid gland
January 24, 2019 - Proteus Digital Health Launches Digital Oncology Medicines to Improve Patient Outcomes
January 24, 2019 - Study looking to prevent type 1 diabetes follows children into adolescence
January 24, 2019 - Nice doctors make a difference
January 23, 2019 - Blood vessel discovery could advance our knowledge of osteoporosis
January 23, 2019 - New esophageal cancer test uses genetic biomarkers to detect changes in esophagal cells
January 23, 2019 - Study evaluates first-ever Robotic Visualization System for neurosurgery
January 23, 2019 - Scientists reveal new mechanism that could lead to specific treatment of strokes and seizures
January 23, 2019 - Both educational level and occupational orientation predict mother’s smoking during pregnancy
January 23, 2019 - How to (gently) get your child to brush their teeth
January 23, 2019 - Short-term hospital readmissions for gun injuries cost $86 million a year | News Center
January 23, 2019 - New certified reference material for testing residual solvents in cannabis
January 23, 2019 - Gene-edited chickens could prevent future flu pandemic
January 23, 2019 - Cardiovascular disease risk begins even before birth
January 23, 2019 - Younger patients receiving kidney transplant more likely to live longer, shows data
January 23, 2019 - Skin samples hold early signs of prion disease, research suggests
January 23, 2019 - Researchers discover how body initiates repair mechanisms that limits damage to myelin sheath
January 23, 2019 - Fecal transplant from certain donors better than others
January 23, 2019 - Risk for Uninsurance in AMI Patients Reduced With Medicaid Expansion
January 23, 2019 - Readmissions reduction program may be associated with increase in patient-level mortality
January 23, 2019 - Fostering translation and communication in medicine and beyond
January 23, 2019 - To Fight Fatty Liver, Avoid Sugary Foods and Drinks
January 23, 2019 - TPU scientists develop new implants that double the rate of bone lengthening in kids
January 23, 2019 - New sessions at Pittcon 2019
January 23, 2019 - Insilico to present latest findings in AI for Drug Discovery at 3rd Annual SABPA FTD Forum
January 23, 2019 - Opioid overdose patients can be safely discharged an hour after administration of naloxone
January 23, 2019 - Scientists find bacterial extracellular vesicles in human blood
January 23, 2019 - Researchers use modified type of flu virus to develop new therapies for prostate cancer
January 23, 2019 - Researchers gain new insights into development of necrotizing enterocolitis in preemies
January 23, 2019 - Medical expert advises people with epilepsy not to stockpile medicines
January 23, 2019 - CDC study explores link between smoking and clinical outcomes of assisted reproductive technology
January 23, 2019 - Study outlines research priorities for improving pediatric patient care and safety
January 23, 2019 - Bedfont to exhibit NObreath FeNO monitor at Arab Health 2019
January 23, 2019 - Nicotinamide riboside supplementation confers significant physiological benefits to mothers and offspring
January 23, 2019 - Increasing temperatures may help preserve crop nutrition
January 23, 2019 - Many Oncologists in the Dark About LGBTQ Health Needs
January 23, 2019 - Epigenetic change causes fruit fly babies to inherit diet-induced heart disease
January 23, 2019 - Erasing memories could reduce relapse rates among drug addicts
January 23, 2019 - African Americans who smoke cigarettes are more likely to develop peripheral artery disease
January 23, 2019 - Unique data combination helps FinnGen researchers to fund links between genetic factors and health
January 23, 2019 - Parents’ mental health problems associated with reactive attachment disorder in children
January 23, 2019 - Graphene Flagship project studies impact of graphene and related materials on our health
January 23, 2019 - The connection between the Pope and contraceptive pills
January 23, 2019 - Prior dengue infection could protect children from symptomatic Zika
January 23, 2019 - Previous dengue virus infection associated with protection from symptomatic Zika
January 23, 2019 - VISTA checkpoint implicated in pancreatic cancer immunotherapy resistance
January 23, 2019 - The Tiny Camera That Could Revolutionize Cardiovascular Surgery
January 23, 2019 - Peptide isolated from soil fungi has antitumor and antibacterial properties
January 23, 2019 - TGen identifies polio-like virus as potential cause of Acute Flaccid Myelitis outbreak
January 23, 2019 - Migrants and refugees do not bring disease and are at greater health risk themselves says WHO
January 23, 2019 - Examing the effects of menopause in workplace
January 23, 2019 - Enemy number 1 – Air pollution and climate change top of WHO agenda
January 23, 2019 - Two Positive Phase III studies of Tafenoquine for the Radical Cure of Plasmodium vivax Malaria Published in The New England Journal of Medicine
January 23, 2019 - World Trade Center responders at increased risk for head and neck cancers
January 23, 2019 - Low-sugar diet leads to significant improvement in nonalcoholic fatty liver disease in boys
January 23, 2019 - Chaos in bodily regulation can optimize our immune system, finds study
January 23, 2019 - Short, text-based exercises can increase happiness for adults recovering from substance use disorders
January 23, 2019 - Body size may have greater influence on women’s lifespan than men
January 23, 2019 - Groundbreaking tool helps visualize neuronal activity with near-infrared light
January 23, 2019 - Prior dengue immunity in children may be protective against symptomatic Zika
January 23, 2019 - Holocaust survivors with PTSD and their offspring exhibit more unhealthy behavior patterns
January 23, 2019 - Scientists discover new genetic mutations causing inherited deaf-blindness
January 23, 2019 - UC team designs new naloxone-dispensing smart device
January 23, 2019 - Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress

First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress

image_pdfDownload PDFimage_print

KENILWORTH, N.J.–(BUSINESS WIRE) October 20, 2018 –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas. MK-1454 is one of more than 20 novel investigational immuno-therapeutic candidates Merck is evaluating as part of its broad oncology pipeline. The findings for MK-1454 were accepted as a late-breaking abstract and are being presented today in a poster discussion session at the ESMO 2018 Congress (Abstract #LBA15).

“Merck is advancing a broad pipeline focused on the development of novel therapies with potential to provide meaningful clinical benefit to people with advanced cancers,” said Dr. Eric H. Rubin, senior vice president, early-stage development, clinical oncology, Merck Research Laboratories. “We are encouraged by these early findings with our STING agonist, most notably the observations of several robust anti-tumor responses in patients receiving MK-1454 in combination with KEYTRUDA. Further studies are ongoing.”

Study Design and Findings for MK-1454 (Abstract #LBA15)

In this Phase 1, open-label, multi-arm, multicenter, dose-escalation clinical trial (NCT03010176), MK-1454 was administered to patients with advanced solid tumors or lymphomas by intratumoral injection every week for nine weeks for three cycles then every three weeks thereafter. Dose escalations for MK-1454 were 10-3,000 µg (MK-1454 monotherapy arm) and 90-2,000 µg (MK-1454 in combination with KEYTRUDA arm) using accelerated titration followed by modified toxicity probability interval design. KEYTRUDA was administered as an intravenous (IV) injection at a dose of 200 mg every three weeks. Patients receiving MK-1454 as monotherapy who progressed while on therapy were eligible for crossover to the MK-1454-KEYTRUDA combination arm. Study objectives included evaluation of safety, tolerability, pharmacodynamics, pharmacokinetics and tumor responses evaluated using RECIST v1.1 criteria.

Interim data presented at ESMO were based on findings from 26 patients enrolled in the MK-1454 monotherapy arm and 25 patients enrolled in the combination arm with KEYTRUDA, plus 9 patients who crossed over from monotherapy to receive the combination regimen. In the monotherapy arm, no complete or partial responses were observed (n=0/20). In the combination arm, partial responses were observed in 24 percent of patients (n=6/25) (three head and neck squamous cell carcinoma, one triple-negative breast cancer, and two anaplastic thyroid carcinoma), with median reductions of 83 percent in the size of both target-injected and non-injected tumors. At the time of analysis, all of the partial responses were ongoing and had lasted six months or longer. None of the responders had previously received a PD-1/PD-L1 inhibitor therapy. The disease control rates were 20 percent and 48 percent for the monotherapy and combination arms, respectively.

Treatment-related adverse events (TRAEs) occurred in 82.6 percent (n=19/23) and 82.1 percent (n=23/28) of patients in monotherapy and combination arms, respectively. TRAEs resulting in trial discontinuation occurred in 7.1 percent of patients (n=2/28) in the combination arm. No TRAE discontinuations were recorded in patients in the monotherapy arm. The most common TRAEs (occurring in ≥10% of patients) in both study arms included: pyrexia, injection site pain, chills, and fatigue. In the monotherapy arm, additional TRAEs occurring in ≥10% of patients included: nausea, myalgia, headache, and tumor pain. In the combination arm, additional TRAEs occurring in ≥10% of patients included: pruritus, diarrhea, rash, and tachycardia.

About STING and MK-1454

STING is a signaling molecule that plays an important role in the body’s first line of defense against pathogens, such as bacteria and viruses (innate immune system). When activated, STING triggers the production of inflammatory proteins that can stimulate the immune system leading to the deployment of T cells, which are important in generating an effective immune mediated response to cancer cells.

Merck is exploring the role of the STING pathway across a variety of tumors as monotherapy and in combination with the company’s anti-PD-1 therapy, KEYTRUDA. MK-1454 is an investigational small molecule STING agonist administered as an intratumoral injection that is currently being evaluated in a Phase 1 clinical trial for the treatment of solid tumors and lymphomas (ClinicalTrials.gov, NCT03010176).

About Merck’s Oncology Pipeline

As an immuno-oncology research leader, Merck is committed to advancing a broad oncology pipeline targeting multiple aspects of cancer cell biology and immune-based pathways. Specifically, Merck is discovering and developing novel targets in four distinct research areas: immune agonists, negative immune regulators, cancer vaccines and immune modulators of the tumor microenvironment including oncolytic viruses. Today, Merck’s pipeline includes more than 20 investigational immuno-therapeutic candidates – including novel combinations with the company’s approved medicines – in both clinical and pre-clinical development.

Merck’s Focus on Cancer

Our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. At Merck, the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. As part of our focus on cancer, Merck is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. We also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Source: Merck

Posted: October 2018

Tagged with:

About author

Related Articles